Although several reports indicate that different cell lines respond differently to TZDs, [30], [31], [32], [33], to our knowledge, a direct comparison between these four TZDs in ovarian cancer and delineating whether these effects are PPARγ dependent using molecular, physiological and pharmacological approaches has not been investigated. The gene discussed is PPARG; the disease is ovarian carcinoma.